Financial market conditions are beginning to improve for biopharmaceutical companies raising money to fund research and development programs, thanks in large part to an increase in mergers and acquisitions that have seen big pharma companies buy small firms at attractive valuations. But while deals are occurring across the preclinical through commercial-stage asset spectrum, the majority of financings – and particularly initial public offerings – still involve companies with drug candidates entering or in the clinic, where buyout valuations give investors the highest returns.
Financial Market At The Start Of An Upswing, For Companies With Focused Strategies
Great Story Not Enough; Milestones Must Be Near And Clear
Investors, advisors and companies that have raised cash recently insist funding is available and IPOs are possible for drug developers that can clearly outline future clinical milestones.
More from BIO
• By
Nauman Shah, head of business development for J&J Innovation, sat down at the BIO CEO & Investor Conference to talk about his trip to China and the state of the biotech scene there.
• By
Sutro Biopharma CEO Bill Newell spoke with Scrip about the company’s novel platform, its goal of improving folate receptor alpha-driven ovarian cancer and its business development strategy.
• By
Scrip spoke with Amgen’s senior VP of US business operations about the impact of drug pricing and reimbursement pressures coming from government policy changes and commercial payers.
• By
Dollars spent on biopharma M&A so far in 2024 may not be as high as in 2023, but dealmakers say deal volume is robust with many factors influencing the overall value of transactions this year.
More from Conferences
• By
All the elements for a big M&A year are in place, but political uncertainty and interest rates could push more deals into the second half of the year, according to business development experts at BIO CEO & Investor.
• By
Highlights from the BIO CEO & Investor Conference, held in New York 10-11 February, include the impact of US political changes, Chinese companies entering the obesity race, and IPO pitfalls.
• By
Bristol Myers Squibb has been in a rapid growth phase to make up for upcoming losses of exclusivity. Scrip spoke with executives about further catalysts coming in the next 18-24 months.